HUMA Humacyte, Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
01:55
Jan 22
Jan 22
Humacyte asymmetric 5-10x on dialysis data
The author argues Humacyte is a real product company, not vaporware, with an FDA-approved product (Symvess) for vascular trauma and military injuries, backed by DoD/BARDA. He sees a multi-billion-dollar dialysis access indication with Phase 3 data and regulatory filings ahead as the key catalyst. The stock trades near all-time lows around $1 support, depressed by biotech dilution and risk-off sentiment, which he frames as asymmetric 5-10x upside on good news. He explicitly labels it high risk.
HIGH
About HUMA Investor Commentary
Across the available history and selected sources, Buzzberg tracks HUMA (Humacyte, Inc.) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: u/Rustic4748.